Pubblicazioni

Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients

2021 - ANNALS OF HEMATOLOGY

Scalzulli, E.; Caocci, G.; Efficace, F.; Rizzo, L.; Colafigli, G.; Di Prima, A.; Pepe, S.; Fegatelli, D. A.; Carmosino, I.; Diverio, D.; Latagliata, R.; La Nasa, G.; Martelli, M.; Foa, R.; Breccia, M.

Infantile inflammatory myofibroblastic tumors. Clinicopathological and molecular characterization of 12 cases

2020 - MODERN PATHOLOGY

Lopez-Nunez, O.; John, I.; Panasiti, R. N.; Ranganathan, S.; Santoro, L.; Grelaud, D.; Wu, T.; Buccoliero, A. M.; Casanova, M.; Alaggio, R.; Surrey, L. F.

Is Less More? Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL

2020 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Chiaretti, S.

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life

2017 - AMERICAN JOURNAL OF HEMATOLOGY

Breccia, Massimo; Colafigli, Gioia; Molica, Matteo; Scalzulli, Emilia; Diverio, Daniela; Latagliata, Roberto; Guarini, Anna; FoÃ , Robin